{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T12:48:32Z","timestamp":1761310112597},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,7,22]],"date-time":"2003-07-22T00:00:00Z","timestamp":1058832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2003,8]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p><jats:bold>Objectives:<\/jats:bold> The <jats:italic>TP53<\/jats:italic> gene encodes a nuclear protein implicated in the regulation of the cell cycle, DNA repair, and apoptosis. <jats:italic>TP53<\/jats:italic> mutations and other alterations have been described in numerous types of tumors, and some of these have been associated with poor prognosis. The aim of this study was to characterize <jats:italic>TP53<\/jats:italic> mutations in childhood B non\u2010Hodgkin's lymphoma, their correlation with clinical prognostic factors and response to therapy.<\/jats:p><jats:p><jats:bold>Patients and methods:<\/jats:bold> Samples from 49 children with B non\u2010Hodgkin's lymphoma were examined for <jats:italic>TP53<\/jats:italic> alterations by single\u2010strand conformation polymorphism analysis (SSCP) of exons 5\u20139, direct sequencing and by p53 immunohistochemistry.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Mutations of <jats:italic>TP53<\/jats:italic> were detected in 11 of 49 (22.5%) patients and more specifically in 20% of Burkitt's lymphoma. The sequence analysis showed missense mutations in 10 cases and an insertion mutation in one case. Mutations of the transition type occurred more frequently than transversions (seven of 11). Analysis of the spectrum of single\u2010nucleotide substitutions showed a 30% frequency of transition mutations in CpG dinucleotide sequences. The overall frequency of p53 immunostaining positivity was 36% (15 of 41). There was a very good agreement between protein expression and the presence of <jats:italic>TP53<\/jats:italic> mutation (<jats:italic>P<\/jats:italic>\u2003=\u20030.0005). No significant correlation was found regarding age, gender, clinical stage and LDH level and <jats:italic>TP53<\/jats:italic> mutations. Comparison of EFS curves using the log\u2010rank test were also not significant. However, the analysis of the effects of mutations on the core p53 structure identified biological and biochemical mutants with phenotypes probably related to different response to chemotherapy.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our data suggest that some types of mutants can alter the protein distinctly and may be associated with a more aggressive phenotype. In addition, the impact of <jats:italic>TP53<\/jats:italic> mutations on response to therapy may also be influenced by disruption of other genes.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2003.00094.x","type":"journal-article","created":{"date-parts":[[2003,7,22]],"date-time":"2003-07-22T16:10:48Z","timestamp":1058890248000},"page":"81-90","source":"Crossref","is-referenced-by-count":22,"title":["DNA sequence profile of <i>TP53<\/i> gene mutations in childhood B\u2010cell non\u2010Hodgkin's lymphomas: prognostic implications"],"prefix":"10.1111","volume":"71","author":[{"given":"Claudete Esteves","family":"Klumb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Rodrigues","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00eddia Maria","family":"Magalh\u00e3es de Resende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Kadma","family":"Carri\u00e7o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Moellman","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"de Meis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Ciuvalschi","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin David","family":"Rumjanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7,22]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00171-9"},{"key":"e_1_2_17_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2006.11.012"},{"key":"e_1_2_17_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81871-1"},{"key":"e_1_2_17_5_2","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis","volume":"54","author":"Greenblatt MS","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.7.1847"},{"key":"e_1_2_17_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0593-42"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202314"},{"key":"e_1_2_17_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796-811"},{"key":"e_1_2_17_10_2","first-page":"598","volume":"58","author":"Young JL","year":"1996","journal-title":"Cancer incidence, survival and mortality for children younger than age 15\u2003years. Cancer"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.40.6.355"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710303371802"},{"key":"e_1_2_17_13_2","first-page":"3294","article-title":"Improved treatment results in childhood B\u2010cell neoplasms with tailored intensification of therapy: a report of Berlin\u2013Frankfurt\u2013M\u00fcnsten Group trial NLH\u2010BFM 90","volume":"94","author":"Reiter A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_17_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202384"},{"key":"e_1_2_17_15_2","first-page":"2155","article-title":"Meijer\u2010van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer","volume":"60","author":"Berns EM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_17_16_2","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with agressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez L","year":"1996","journal-title":"Blood"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370804"},{"key":"e_1_2_17_18_2","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B\u2010cell non\u2010Hodgkin's lymphoma","volume":"90","author":"Koduru PR","year":"1997","journal-title":"Blood"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2412.2412"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.12.5413"},{"key":"e_1_2_17_21_2","first-page":"4273","article-title":"The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors","volume":"52","author":"Bhatia KG","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_17_22_2","first-page":"567","article-title":"Prognostic significance of p53 mutations in small non\u2010cleaved cell lymphomas","volume":"4","author":"Gutierrez MI","year":"1994","journal-title":"Int J Oncol"},{"key":"e_1_2_17_23_2","first-page":"550","article-title":"Mutational analysis of p53 in 16 cases of acute lymphoblastic leukemia and Burkitt's lymphoma","volume":"82","author":"Nomded\u00e9u JF","year":"1997","journal-title":"Haematologica"},{"key":"e_1_2_17_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.812"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-31802001000600006"},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_17_27_2","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: dissimilarities from lymphoma in adults","volume":"7","author":"Murphy SB.","year":"1980","journal-title":"Semin Oncol"},{"key":"e_1_2_17_28_2","first-page":"153","volume-title":"PCR Protocols: A guide to Methods and Applications","author":"Wright DK"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(91)90120-I"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65461-2"},{"key":"e_1_2_17_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5463"},{"key":"e_1_2_17_32_2","first-page":"1691","article-title":"Polymorphism at codon 213 within the p53 gene","volume":"9","author":"Carbone D","year":"1991","journal-title":"Oncogene"},{"key":"e_1_2_17_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1905840"},{"key":"e_1_2_17_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.1380030207"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/35106009"},{"key":"e_1_2_17_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08911.x"},{"key":"e_1_2_17_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.205"},{"key":"e_1_2_17_38_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8023157"},{"key":"e_1_2_17_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203285"},{"key":"e_1_2_17_40_2","first-page":"6788","article-title":"Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome","volume":"60","author":"Sigal A","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_17_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.10032"},{"key":"e_1_2_17_42_2","doi-asserted-by":"publisher","DOI":"10.1385\/1592590845"},{"key":"e_1_2_17_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61686-0"},{"key":"e_1_2_17_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401901"},{"key":"e_1_2_17_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200301000-00002"},{"key":"e_1_2_17_46_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.9.3963"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2003.00094.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2003.00094.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2003.00094.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:30:06Z","timestamp":1697229006000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2003.00094.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,22]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["10.1034\/j.1600-0609.2003.00094.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2003.00094.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,22]]}}}